CN1165310C - 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物) - Google Patents

含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物) Download PDF

Info

Publication number
CN1165310C
CN1165310C CNB008034702A CN00803470A CN1165310C CN 1165310 C CN1165310 C CN 1165310C CN B008034702 A CNB008034702 A CN B008034702A CN 00803470 A CN00803470 A CN 00803470A CN 1165310 C CN1165310 C CN 1165310C
Authority
CN
China
Prior art keywords
drug
inhibitor
agent
isoenzyme
inducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008034702A
Other languages
English (en)
Chinese (zh)
Other versions
CN1338936A (zh
Inventor
A
A·拉扎
J·S·佩尔斯
�������ɭ
H·G·胡钦森
���ڿ���
D·施内克
T·巴巴
A·托赤
Ų�������޹������޹�˾
Y·雅马古赤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
AstraZeneca AB
Original Assignee
Shionogi and Co Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1165310(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Shionogi and Co Ltd, AstraZeneca AB filed Critical Shionogi and Co Ltd
Publication of CN1338936A publication Critical patent/CN1338936A/zh
Application granted granted Critical
Publication of CN1165310C publication Critical patent/CN1165310C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB008034702A 1999-02-06 2000-02-01 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物) Expired - Lifetime CN1165310C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GB9902593.4 1999-09-08
GB9921064.3 1999-09-08
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GB9921063.5 1999-09-08
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination

Publications (2)

Publication Number Publication Date
CN1338936A CN1338936A (zh) 2002-03-06
CN1165310C true CN1165310C (zh) 2004-09-08

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008034702A Expired - Lifetime CN1165310C (zh) 1999-02-06 2000-02-01 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物)

Country Status (28)

Country Link
US (3) US6982157B1 (enExample)
EP (1) EP1185274B1 (enExample)
JP (2) JP2002536331A (enExample)
KR (2) KR20010101790A (enExample)
CN (1) CN1165310C (enExample)
AR (1) AR029333A1 (enExample)
AT (1) ATE282415T1 (enExample)
AU (1) AU767304B2 (enExample)
BR (1) BR0007999A (enExample)
CA (1) CA2358632C (enExample)
CZ (1) CZ301296B6 (enExample)
DE (1) DE60015965T2 (enExample)
EE (1) EE04929B1 (enExample)
EG (1) EG23858A (enExample)
ES (1) ES2232418T3 (enExample)
GB (1) GB0000710D0 (enExample)
ID (1) ID30485A (enExample)
IL (1) IL144715A0 (enExample)
IS (1) IS2337B (enExample)
MX (1) MXPA01007905A (enExample)
MY (1) MY130606A (enExample)
NO (1) NO320745B1 (enExample)
NZ (1) NZ512982A (enExample)
PL (1) PL198034B1 (enExample)
PT (1) PT1185274E (enExample)
TR (1) TR200102228T2 (enExample)
TW (1) TWI282738B (enExample)
WO (1) WO2000045817A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1680091B1 (en) 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S A solid dosage form comprising a fibrate
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1786414A4 (en) 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
US20090162316A1 (en) 2005-07-05 2009-06-25 Harvard University Liver targeted conjugates
JP5235676B2 (ja) * 2005-12-20 2013-07-10 レツク・フアーマシユーテイカルズ・デー・デー （ｅ）−７−〔４−（４−フルオロフェニル）−６−イソプロピル−２−〔メチル（メチルスルホニル）アミノ〕ピリミジン−５−イル〕−（３ｒ，５ｓ）−３，５−ジヒドロキシヘプタ−６−エン酸を含む医薬組成物
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
US11417416B2 (en) * 2018-06-14 2022-08-16 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
RS63740B1 (sr) 2019-07-31 2022-12-30 Intas Pharmaceuticals Ltd Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
ES2065113T3 (es) * 1991-07-02 1995-02-01 Benckiser Gmbh Joh A Botella de almacenamiento plegable.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity

Also Published As

Publication number Publication date
EG23858A (en) 2007-11-18
PL198034B1 (pl) 2008-05-30
AU2121800A (en) 2000-08-25
CN1338936A (zh) 2002-03-06
CA2358632A1 (en) 2000-08-10
PT1185274E (pt) 2005-03-31
EE04929B1 (et) 2007-12-17
EP1185274B1 (en) 2004-11-17
IL144715A0 (en) 2002-06-30
PL364780A1 (en) 2004-12-13
TR200102228T2 (tr) 2002-03-21
BR0007999A (pt) 2001-11-06
EE200100406A (et) 2002-10-15
GB0000710D0 (en) 2000-03-08
WO2000045817A1 (en) 2000-08-10
CZ20012844A3 (cs) 2001-11-14
DE60015965T2 (de) 2006-01-05
NO20013811D0 (no) 2001-08-03
KR20010101790A (ko) 2001-11-14
US20060040969A1 (en) 2006-02-23
NO20013811L (no) 2001-10-02
ATE282415T1 (de) 2004-12-15
NO320745B1 (no) 2006-01-23
CA2358632C (en) 2008-10-28
KR20060117381A (ko) 2006-11-16
IS6009A (is) 2001-07-17
CZ301296B6 (cs) 2010-01-06
DE60015965D1 (de) 2004-12-23
MXPA01007905A (es) 2003-06-04
IS2337B (is) 2008-02-15
ES2232418T3 (es) 2005-06-01
HK1041817A1 (en) 2002-07-26
AR029333A1 (es) 2003-06-25
ID30485A (id) 2001-12-13
US20090042911A1 (en) 2009-02-12
TWI282738B (en) 2007-06-21
MY130606A (en) 2007-07-31
JP2007277267A (ja) 2007-10-25
AU767304B2 (en) 2003-11-06
US6982157B1 (en) 2006-01-03
NZ512982A (en) 2003-08-29
EP1185274A1 (en) 2002-03-13
JP2002536331A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
CN1338936A (zh) 含有(e)－7－[4－(4－氟苯基)－6－异丙基－2－[甲基(甲基磺酰基)氨基]嘧啶－5基](3r,5s)－3,5－二羟基庚－6－烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物
CN100346788C (zh) 用于鼻内给药的芬太尼组合物
CN1211079C (zh) 稳定的缓释口服给药组合物
CN1244801A (zh) 用于糖尿病的磺酰脲类－格列酮类协同联合给药
CN1215338A (zh) 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
CN1087517A (zh) 用于降低高半胱氨酸水平的药物制剂
CN1658867A (zh) 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
CN1382440A (zh) 用于治疗抑郁症或预防认知功能退化的方法和药盒
CN1557352A (zh) 菊苣水提取物的新用途
CN1294925C (zh) 一种治疗高血压和高血脂的中药及其制备方法
RU2233162C2 (ru) Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4
CN1282457C (zh) 治疗高血脂症的组合物
CN1568993A (zh) 治疗高血脂症的组合物
CN1372476A (zh) 药物组合物
CN1323665C (zh) 治疗高血脂症的组合物
CN1692906A (zh) 治疗高血脂症的组合物
CN1960781A (zh) 治疗阿尔茨海默氏病的治疗组合
CN1692905A (zh) 治疗高血脂症的组合物
HK1041817B (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
CN1646167A (zh) 代谢综合症的治疗
ZA200105838B (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4.
CN1672683A (zh) 治疗高血脂症的组合物
CN1903364A (zh) 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物
HK1024180A (en) Sulfonylurea-glitazone synergistic combinations for diabetes
CN1835959A (zh) 用选择性雄激素受体调节剂治疗骨相关病症

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040908

CX01 Expiry of patent term